SCHEMBL1011438

SCHEMBL1011438

COC(=O)c1ccc(CN(Cc2c(Cl)cncc2Cl)c2ccc(OC)c(OC)c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 6/20 0.53
MAPT P10636 4/20 0.43
KMT2A Q03164 4/20 0.43
QPCT Q16769 2/20 0.41
GLA P06280 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
LMNA P02545 1/20 0.41
PDE4A P27815 3/20 0.41
PDE4B Q07343 3/20 0.41
PDE4C Q08493 3/20 0.41
ACHE P22303 1/20 0.41
MEN1 O00255 1/20 0.40
CYP2B6 P20813 1/20 0.40
CCR5 P51681 1/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3450744 0.92 CA1 (0.46) PDE4DMAPTKMT2ALMNAPDE4A
SCHEMBL1011460 0.91 PDE4D (0.54) PDE4DKMT2ASMN1; SMN2LMNAACHE
SCHEMBL1008748 0.86 PDE4D (0.45) PDE4DMAPTKMT2AQPCTSMN1; SMN2
SCHEMBL1008443 0.85 PDE4D (0.47) PDE4DKMT2ACYP1A2CYP3A4SMN1; SMN2
SCHEMBL1008845 0.85 PDE4D (0.44) PDE4DMAPTKMT2AQPCTSMN1; SMN2
SCHEMBL1009113 0.83 PDE4D (0.45) PDE4DQPCTCYP2C19PDE4APDE4B
SCHEMBL1009086 0.82 PDE4D (0.43) PDE4DKMT2APDE4APDE4BPDE4C
SCHEMBL1008929 0.81 PDE4D (0.44) PDE4DKMT2AQPCTMEN1ALDH1A1
SCHEMBL1065950 0.81 CA1 (0.45) PDE4DPDE4APDE4BPDE4CALDH1A1
SCHEMBL1010197 0.79 PDE4D (0.44) PDE4DQPCTPDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2268632-B1 TERTIARY AMINE DERIVATIVES AS PHOSPHODIESTERASE-4 INHIBITORS CHIESI FARMA SPA (IT) 2012-08-08 EP claimed
EP-2268632-A1 TERTIARY AMINE DERIVATIVES AS PHOSPHODIESTERASE-4 INHIBITORS CHIESI FARMACEUTICI S.p.A. (IT) 2011-01-05 EP claimed
WO-2009127320-A1 TERTIARY AMINE DERIVATIVES AS PHOSPHODIESTERASE-4 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2009-10-22 WO claimed
EP-2110375-A1 Phosphodiesterase-4 inhibitors belonging to the tertiary amine class CHIESI FARMACEUTICI S.p.A. (IT) 2009-10-21 EP claimed
US-20090258905-A1 PHOSPHODIESTERASE-4 INHIBITORS BELONGING TO THE TERTIARY AMINE CLASS CHIESI FARMACEUTICI S.P.A. (IT) 2009-10-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258905-A1 PHOSPHODIESTERASE-4 INHIBITORS BELONGING TO THE TERTIARY AMINE CLASS PDE4A, PDE4B, PDE2A PDE4D 9/4885MAPT 3900/4885KMT2A 1051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.